{
    "clinical_study": {
        "@rank": "92320", 
        "acronym": "BLESS", 
        "arm_group": [
            {
                "arm_group_label": "Prasugrel dose 5 mg/day", 
                "arm_group_type": "Experimental", 
                "description": "225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of  100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 5 mg/day of prasugrel for 12 months"
            }, 
            {
                "arm_group_label": "Prasugrel dose 10 mg/day", 
                "arm_group_type": "Active Comparator", 
                "description": "225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of  100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 10 mg/day of prasugrel for 12 months"
            }
        ], 
        "brief_summary": {
            "textblock": "Aim:  to verify if after the acute phase of ACS acute coronary syndrome (1-months), from 1\n      to 12 months the reduction of maintenance dose of prasugrel from 10 mg to 5 mg/day may\n      reduce the bleeding events (5 mg vs 10 mg). All patients will be treated with 325 mg of\n      aspirin followed by a maintenance dosage of  100 mg of aspirin for at least 1 year. At\n      baseline (after 60 mg loading dose of prasugrel) and after 1 month (7 days after the\n      randomization at 10 or 5 mg of prasugrel) all patients will undergo light transmittance\n      aggregometry (LTA) test to evaluate residual platelet reactivity (pharmacodynamic effects)."
        }, 
        "brief_title": "BLeeding Events and Maintenance DoSe of PraSugrel", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Adverse Reaction to Antiplatelet Agent", 
            "Acute Coronary Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Acute Coronary Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  all ACS patients treated with PCI (percutaneous coronary intervention) and dual\n             antiplatelet therapy (DAPT: aspirin plus prasugrel).\n\n          -  Informed written consent\n\n        Exclusion Criteria:\n\n          -  Age < 18 years\n\n          -  Active bleeding; bleeding diathesis; coagulopathy\n\n          -  History of gastrointestinal or genitourinary bleeding <2 months\n\n          -  Major surgery in the last 6 weeks\n\n          -  History of intracranial bleeding or structural abnormalities\n\n          -  Suspected aortic dissection\n\n          -  Any previous TIA (transient ischemic attack)/stroke\n\n          -  Administration in the week before the index event of clopidogrel, ticlopidine,\n             prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or\n             fondaparinux .\n\n          -  Known relevant hematological deviations: Hb <10 g/dl, Thrombocytopenia. <100x10^9/l\n\n          -  Use of coumadin derivatives within the last 7 days\n\n          -  Chronic therapy with prasugrel or ticagrelor\n\n          -  Known malignancies or other comorbid conditions with life expectancy <1 year\n\n          -  Known severe liver disease, severe renal failure\n\n          -  Known allergy to the study medications\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790854", 
            "org_study_id": "BLESS Study"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prasugrel dose 5 mg/day", 
                "intervention_name": "Prasugrel dose 5 mg/day", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Prasugrel dose 10 mg/day", 
                "intervention_name": "Prasugrel dose 10 mg/day", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Prasugrel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "prasugrel", 
            "antiplatelet", 
            "Acute Coronary Syndrome"
        ], 
        "lastchanged_date": "February 12, 2013", 
        "location": {
            "contact": {
                "email": "david.antoniucci@virgilio.it", 
                "last_name": "David Antoniucci, MD", 
                "phone": "+390557947966"
            }, 
            "contact_backup": {
                "email": "n.carrabba@virgilio.it", 
                "last_name": "Nazario Carrabba, MD", 
                "phone": "+390557947966"
            }, 
            "facility": {
                "address": {
                    "city": "Florence", 
                    "country": "Italy"
                }, 
                "name": "Careggi Hospital"
            }, 
            "investigator": {
                "last_name": "David Antoniucci, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Bless Study (BLeeding Events and Maintenance DoSe of PraSugrel)", 
        "other_outcome": [
            {
                "description": "pharmacodynamic effects of shifting prasugrel maintenance dose from 10 mg to 5 mg after ACS", 
                "measure": "pharmacodynamic effects", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "correlation between residual platelet reactivity (LTA), both at baseline and at 1-month, with bleeding and ischemic events", 
                "measure": "residual platelet reactivity (LTA)", 
                "safety_issue": "Yes", 
                "time_frame": "baseline - 1 month"
            }
        ], 
        "overall_contact": {
            "email": "david.antoniucci@virgilio.it", 
            "last_name": "David Antoniucci, MD", 
            "phone": "+390557947966"
        }, 
        "overall_contact_backup": {
            "email": "n.carrabba@virgilio.it", 
            "last_name": "Nazario Carrabba, MD", 
            "phone": "+390557947966"
        }, 
        "overall_official": {
            "affiliation": "Careggi Hospital, division of Invasive Cardiology", 
            "last_name": "David Antoniucci, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "major, minor and minimal bleeding defined according BARC (Bleeding Academic Research Consurtium criteria (11), occurring from 1 month to the end of the study.", 
            "measure": "bleeding", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790854"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Careggi Hospital", 
            "investigator_full_name": "David Antoniucci", 
            "investigator_title": "Head Division of Invasive Cardiology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "MACE (cardiac death, Myocardial Infarction, stroke) occurring from 1 month to the end of the study; late stent thrombosis.", 
            "measure": "MACE", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Careggi Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "ARCARD ONLUS Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "David Antoniucci", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}